Evidence map›Paper›PMID 29416820›Full record

ArticleOncotarget2018

Predictive factors for 6

Vincenzo Formica, Maria Teresa Ionta, Bruno Massidda, Giacomo Vessia, Luigi Maiorino, Rossana Casaretti, Donato Natale, Giuseppe Barberis, Gianfranco Filippelli, Ettore Greco and 6 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
  2. An economic analysis of Chemo MouthpieceJournal of comparative effectiveness research · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Vincenzo FormicaDepartment of Systems Medicine, Medical Oncology Unit, Tor Vergata University Hospital, Rome, Italy.
Maria Teresa IontaMedical Oncology II, Azienda Ospedaliero, Universitaria di Cagliari, Cagliari, Italy.
Bruno MassiddaMedical Oncology II, Azienda Ospedaliero, Universitaria di Cagliari, Cagliari, Italy.
Giacomo VessiaOncologia Medica, Ospedale Della Murgia, Altamura, Italy.
Luigi MaiorinoDepartment of Medical Oncology, Napoli, Italy.
Rossana CasarettiIstituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione G. Pascale"- IRCCS, Naples, Italy.
Donato NataleOspedale Civile San Massimo, Pescara, Italy.
Giuseppe BarberisOncologia Medica, Ospedale Evangelico Villa Betania, Napoli, Italy.
Gianfranco FilippelliOspedale S. Francesco di Paola, Paola CS, Italy.
Ettore GrecoOncologia Medica, P.O. Lamezia Terme, Italy.
Livio BlasiUOC Oncologia Medica, ARNAS Civico, Palermo, Italy.
Sergio MancarellaOncologia Medica, Presidio Ospedaliero S Caterina, Galatina, Italy.
Anna RussoOncologia Medica, Policlinico "Paolo Giaccone", Palermo, Italy.
Enrico BarbatoOncologia medica, Ospedale " Moscati " Aversa, Aversa, Italy.
Liberato Di LulloOncologia Medica, Ospedale F. Veneziale, Isernia, Italy.
Mario RoselliDepartment of Systems Medicine, Medical Oncology Unit, Tor Vergata University Hospital, Rome, Italy.
Azienda Ospedaliero-Universitaria Cagliari · ITMedica (Italy) · ITAzienda Ospedaliera S.Giuseppe Moscati · ITAzienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo · ITIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITOspedale Civile di Venezia · ITPresidio Ospedaliero · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early switching to de-intensified maintenance regimen is still a matter of debate in metastatic colorectal cancer (mCRC). The MARTHA trial, a S.I.C.O.G. phase III randomized trial, compared FOLOFIRI+bevacizumab (B) for 12 cycles (6 months) followed by B for up to 12 months (FOLFIRI +B*12 arm)

Indexed as

bevacizumabdeath pace analysisfluorouracilirinotecanmetastatic colorectal cancer

Identifiers

PMID29416820
PMCPMC5788688
OpenAlexW2772515606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.